Claims
- 1. A method of producing a ligand:receptor complex, comprising contacting:
a) a substantially pure or recombinant mammalian IL-1δ or IL-L1ε with a receptor comprising the IL-1R6 receptor subunit; or b) a mammalian IL-1δ or IL-1ε with a receptor comprising a substantially pure or recombinant IL-1R6 receptor subunit; thereby allowing said complex to form.
- 2. The method of claim 1, wherein:
a) said complex results in modulation of NFκB activation; b) said receptor is on a cell; c) said complex formation results in a physiological change in the cell expressing said receptor; d) said contacting is in combination with an anti-inflammatory agent; or e) said contacting allows quantitative detection of said ligand.
- 3. The method of claim 2, wherein said receptor is on a skin cell.
- 4. A method of modulating physiology or development of an IL-1R6 receptor expressing cell comprising contacting said cell to an exogenous agonist or antagonist of a mammalian IL-1δ or IL-1ε.
- 5. The method of claim 4, wherein:
A) said antagonist is:
1) an antibody which:
a) neutralizes said mammalian IL-1δ; or b) neutralizes said mammalian IL-1ε; or 2) a mutein of said IL-1δ or IL-1ε; B) said physiology is selected from:
1) proliferation; 2) tissue remodeling; or 3) production of inflammatory mediators, including cytokines, chemokines, or adhesion molecules; or C) said modulating is specific for epithelial cells and not endothelial cells.
- 6. The method of claim 4, wherein:
a) said antagonist is an antibody and said physiology is an inflammatory response; or b) said modulating is specific for Th2 cells and not Th1 cells.
- 7. The method of claim 4, wherein said modulating is blocking, and said physiology is an inflammatory response.
- 8. A method of modulating a signal to a cell mediated by IL-1δ or IL-1ε comprising contacting said cell to an administered agonist or antagonist of IL-1R6.
- 9. The method of claim 8, wherein said modulating is inhibiting, and said signal is a pro-inflammatory signal.
- 10. The method of claim 9, wherein:
a) said antagonist is a neutralizing antibody to IL-1R6; b) said agonist or antagonist is administered in combination with an antagonist or agonist of CXCR1, CXCR2, or CCR6; or c) said agonist or antagonist is administered in combination with a growth factor, cytokine, chemokine, or immune adjuvant.
- 11. The method of claim 9, wherein said contacting is with another anti-inflammatory agent.
- 12. A method of selectively labeling a population of cells, said method comprising contacting said cells with an IL-1R6 antibody or a cytokine selected from IL-1δ or IL-1ε, thereby resulting in the identification of cells expressing IL-1R6.
- 13. The method of claim 12, wherein:
a) said contacting results in modulation of NFκB activation; b) said labeling allows purification of IL-1R6+ cells; or c) said labeling allows depletion of IL-1R6+ cells.
- 14. A population of cells made by the method of claim 13.
- 15. The population of claim 14, which:
a) bind anti-IL-1R6 antibody or antiserum; or c) are prepared by Fluorescent Activated Cell Sorting with a labeled IL-1R6 selective:
1) ligand; 2) antibody; or 3) binding compound comprising the antigen binding portion from an antibody which selectively binds IL-1R6.
- 16. A method of testing a compound for ability to affect IL-1R6 receptor-ligand interaction, said method comprising comparing the interaction of IL-1R6 with IL-1δ or IL-1ε in the presence and absence of said compound.
- 17. The method of claim 16, wherein said compound is an antibody against IL-1R6, IL-1δ, or IL-1ε.
- 18. An isolated or recombinant polynucleotide which:
a) encodes at least 15 contiguous amino acid residues of SEQ ID NO: 2; b) encodes at least two distinct segments of at least 8 contiguous amino acid residues of SEQ ID NO 2; c) comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 1; d) encodes at least 15 contiguous amino acid residues of SEQ ID NO: 4; e) encodes at least two distinct segments of at least 8 contiguous amino acid residues of SEQ ID NO 4; or f) comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 3.
- 19. An isolated or recombinant antigenic polypeptide comprising at least:
a) one segment of 12 identical contiguous amino acids from SEQ ID NO: 2; b) at least two distinct segments of 8 identical contiguous amino acids from SEQ ID NO: 2; c) one segment of 12 identical contiguous amino acids from SEQ ID NO: 4; or d) at least two distinct segments of 8 identical contiguous amino acids from SEQ ID NO: 4.
- 20. A binding compound comprising an antigen binding portion from an antibody which binds with selectivity to a polypeptide of claim 19.
Parent Case Info
[0001] This filing is a U.S. Utility Patent Application, which claims the benefit of filing of U.S. Provisional Patent Application, U.S. Ser. No. 60/179,638, filed Feb. 2, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60179638 |
Feb 2000 |
US |